We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.1B
1-Year Est. Return 799.93%
This Fund
S&P 500
This Quarter Est. Return
+17.48%
1 Year Est. Return
+799.93%
3 Year Est. Return
+7,491.17%
5 Year Est. Return
+13,644.18%
10 Year Est. Return
+154,603.62%
AUM
$1.1B
AUM Growth
-$108M
Cap. Flow
-$186M
Cap. Flow %
-16.99%
Top 10 Hldgs %
52.4%
Holding
53
New
7
Increased
6
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$29.3M
2
AVBP icon
ArriVent BioPharma
AVBP
+$23.5M
3
ABVX
Abivax
ABVX
+$19.8M
4
ACHV icon
Achieve Life Sciences
ACHV
+$13.1M
5
EDIT icon
Editas Medicine
EDIT
+$10.4M

Top Sells

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$115M
2
TERN
Terns Pharmaceuticals
TERN
+$70.4M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$21.5M
4
TNGX icon
Tango Therapeutics
TNGX
+$19.2M
5
MANE
Veradermics Inc
MANE
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
51
DELISTED
Terns Pharmaceuticals
TERN
– –
-1,334,418
Closed -$70.4M
VRDN icon
52
Viridian Therapeutics
VRDN
$2.54B
– –
-166,288
Closed -$3.25M
MANE
53
Veradermics Inc
MANE
$4.28B
– –
-300,000
Closed -$18.9M
1 2
3

Similar funds

JVBC
J.V. Bruni & Co Colorado Springs, Colorado $1.1B AUM 38.56% 1-Year Est. Return
WAM
Wellesley Asset Management Portsmouth, New Hampshire $1.1B AUM 0% 1-Year Est. Return
RDWM
Red Door Wealth Management Memphis, Tennessee $1.1B AUM 31.77% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return
GA
Goldstein Advisors Madison, Wisconsin $1.09B AUM 23.69% 1-Year Est. Return
BMM
Berkshire Money Management Dalton, Massachusetts $1.09B AUM 20.64% 1-Year Est. Return
TLIC
Taiyo Life Insurance Company Chuo-Ku, Tokyo, Japan $1.09B AUM 26.68% 1-Year Est. Return
KI
Koch Inc Wichita, Kansas $1.09B AUM 59.79% 1-Year Est. Return

Vivo Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Vivo Capital held 53 positions worth $1.1B, down 9% from $1.2B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Vivo Capital withdrew a net $186M in Q2 2026, closing 6 positions and reducing 8 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $70.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Vivo Capital opened a new position in Achieve Life Sciences worth $18M.

  • Vivo Capital's largest Q2 2026 buy was Achieve Life Sciences: 2,751,032 shares worth $18M.
  • Vivo Capital added most to Tenax Therapeutics in Q2 2026, an estimated $29.3M increase.
  • Vivo Capital's biggest Q2 2026 reduction was Erasca, cutting an estimated $115M.
  • Vivo Capital fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $70.4M.
  • Vivo Capital's ten largest holdings make up 52% of its $1.1B portfolio in Q2 2026.
  • Vivo Capital opened 7 new positions and closed 6 in Q2 2026.
  • Vivo Capital's portfolio value fell 9% quarter-over-quarter to $1.1B.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.